Dr. Reddy's Laboratories Hits Oversold Status (RDY)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 31 2025
0mins
Should l Buy RDY?
Source: NASDAQ.COM
Dr. Reddy's Laboratories Oversold Status: Shares of Dr. Reddy's Laboratories Ltd. (RDY) have entered oversold territory with an RSI reading of 29.9, indicating potential exhaustion of recent selling pressure.
Current Share Performance: The stock traded as low as $13.20 per share, with a recent price of $13.29, compared to its 52-week low of $12.26 and high of $16.17.
Comparison with S&P 500 ETF: The current RSI for the S&P 500 ETF (SPY) is 63.0, highlighting a significant difference in market momentum between RDY and the broader market.
Investment Opportunity: Bullish investors may view the low RSI reading as a potential entry point for buying shares of RDY as selling pressure may be waning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RDY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RDY
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coya Therapeutics Secures $11.1 Million in Private Placement
- Funding Amount: Coya Therapeutics has secured approximately $11.1 million through a private placement of 2,522,727 shares at $4.40 each, reflecting strong market confidence in its biologics development.
- Key Investors: The primary investors include Dr. Reddy’s Laboratories, contributing $10 million, and Greenlight Capital with $1.1 million, indicating a positive outlook from institutional investors regarding Coya's future prospects.
- Use of Proceeds: The company intends to utilize the proceeds to accelerate technology transfer and scale-up manufacturing for low-dose IL-2, supporting the commercial readiness of COYA 302, thereby enhancing its competitive position in the neurodegenerative disease market.
- Compliance Commitment: Coya has committed to filing a registration statement with the SEC within 45 days post-closing, ensuring the legal resale of the securities, which will bolster investor confidence and facilitate future capital operations.
See More
Dr. Reddy's Laboratories (RDY) Reports Q3 EPS of ₹14.52 and Revenue of ₹87.27 Billion
- Earnings Highlights: Dr. Reddy's reported a Q3 GAAP EPS of ₹14.52, reflecting the company's profitability amid current market challenges, indicating resilience in its operations.
- Revenue Growth: The company achieved a revenue of ₹87.27 billion in Q3, marking a 4.4% year-over-year increase, which demonstrates a stable growth trend in the pharmaceutical market and boosts investor confidence.
- Market Reaction: Despite exaggerated headwinds, analysts believe the company's future potential is underappreciated, potentially providing a favorable buying opportunity for investors.
- Product Approval: Dr. Reddy's received approval for the generic version of Ozempic in India, further expanding its product line and is expected to positively impact future revenues.
See More
Dr. Reddy's Laboratories (RDY) Secures Approval for Generic Ozempic, Plans to Produce 12M Pens in First Year
- Market Opportunity: Dr. Reddy's has received approval from India's drug regulator to launch a generic version of Novo Nordisk's Ozempic, expected to hit the market in March, marking a significant advancement in diabetes treatment for the company.
- Competitive Pricing Strategy: CEO M. V. Ramana stated that Dr. Reddy's aims to sell the product at 'competitive pricing' to ensure affordability for patients, thereby expanding its market share in the diabetes segment.
- Production Plans: The company plans to manufacture 12 million Ozempic pens in the first year, demonstrating strong confidence in market demand while also partnering with other firms to promote the treatment.
- Regulatory Review Progress: Additionally, Dr. Reddy's generic version of Wegovy is currently undergoing regulatory review in India, further strengthening the company's position in the weight-loss drug market and potentially supporting future revenue growth.
See More
Asian Equities Surge as American Depositary Receipts Rise Sharply
- Market Recovery: On Wednesday, Asian equities showed strong performance during US trading hours, particularly with American Depositary Receipts (ADRs) rising sharply, indicating a rebound in investor confidence that could drive related companies' stock prices higher.
- Improved Investor Sentiment: The surge in ADRs reflects a notable improvement in market sentiment, suggesting that investors are optimistic about global economic recovery, which may lead to increased capital inflows into Asian markets.
- Increased Trading Volume: The strong performance of ADRs was accompanied by a significant increase in trading volume, indicating a rising interest among market participants in Asian companies, potentially resulting in higher liquidity and better market pricing.
- Positive Future Outlook: Analysts suggest that the upward trend in Asian equities may continue, especially against the backdrop of global economic recovery, prompting investors to focus more on investment opportunities in the Asian market.
See More
Dr. Reddy's (RDY) to Announce Q3 Earnings on January 21, 75% EPS Beat Rate
- Earnings Announcement: Dr. Reddy's is set to release its Q3 earnings report on January 21 before the market opens, generating anticipation among investors regarding its performance.
- EPS Beat Rate: Over the past year, Dr. Reddy's has exceeded earnings per share (EPS) estimates 75% of the time, indicating a consistent ability to deliver strong financial results.
- Revenue Performance: The company has impressively beaten revenue estimates 100% of the time in the last year, showcasing robust market demand and effective execution strategies.
- Market Sentiment: Despite facing exaggerated headwinds, Dr. Reddy's is viewed as having an underappreciated future potential, drawing attention from investors looking for growth opportunities.
See More
Dr. Reddy's Launches 0.7% Olopatadine OTC Eye Drops with $69.9M Market Potential
- Market Launch: Dr. Reddy's has launched a 0.7% antihistamine eye drop in the U.S., becoming the first to market with this product, which is expected to significantly enhance its market share in the OTC eye care sector.
- Sales Potential: According to NIQ data, the Pataday® brand generated approximately $69.9 million in U.S. sales over the past 52 weeks, positioning Dr. Reddy's new product for rapid growth leveraging this market foundation.
- Product Portfolio Expansion: The introduction of this new product enriches Dr. Reddy's existing OTC eye care lineup, further strengthening its competitive edge in the consumer brand market.
- Retail Collaboration Enhancement: The CEO of Dr. Reddy's stated that this launch will deepen collaboration with retail customers, driving the company's strategic positioning in the OTC market and enhancing brand influence.
See More
Coya Therapeutics Secures $11.1 Million in Private Placement
- Funding Amount: Coya Therapeutics has secured approximately $11.1 million through a private placement of 2,522,727 shares at $4.40 each, reflecting strong market confidence in its biologics development.
- Key Investors: The primary investors include Dr. Reddy’s Laboratories, contributing $10 million, and Greenlight Capital with $1.1 million, indicating a positive outlook from institutional investors regarding Coya's future prospects.
- Use of Proceeds: The company intends to utilize the proceeds to accelerate technology transfer and scale-up manufacturing for low-dose IL-2, supporting the commercial readiness of COYA 302, thereby enhancing its competitive position in the neurodegenerative disease market.
- Compliance Commitment: Coya has committed to filing a registration statement with the SEC within 45 days post-closing, ensuring the legal resale of the securities, which will bolster investor confidence and facilitate future capital operations.
See More
Dr. Reddy's Laboratories (RDY) Reports Q3 EPS of ₹14.52 and Revenue of ₹87.27 Billion
- Earnings Highlights: Dr. Reddy's reported a Q3 GAAP EPS of ₹14.52, reflecting the company's profitability amid current market challenges, indicating resilience in its operations.
- Revenue Growth: The company achieved a revenue of ₹87.27 billion in Q3, marking a 4.4% year-over-year increase, which demonstrates a stable growth trend in the pharmaceutical market and boosts investor confidence.
- Market Reaction: Despite exaggerated headwinds, analysts believe the company's future potential is underappreciated, potentially providing a favorable buying opportunity for investors.
- Product Approval: Dr. Reddy's received approval for the generic version of Ozempic in India, further expanding its product line and is expected to positively impact future revenues.
See More
Dr. Reddy's Laboratories (RDY) Secures Approval for Generic Ozempic, Plans to Produce 12M Pens in First Year
- Market Opportunity: Dr. Reddy's has received approval from India's drug regulator to launch a generic version of Novo Nordisk's Ozempic, expected to hit the market in March, marking a significant advancement in diabetes treatment for the company.
- Competitive Pricing Strategy: CEO M. V. Ramana stated that Dr. Reddy's aims to sell the product at 'competitive pricing' to ensure affordability for patients, thereby expanding its market share in the diabetes segment.
- Production Plans: The company plans to manufacture 12 million Ozempic pens in the first year, demonstrating strong confidence in market demand while also partnering with other firms to promote the treatment.
- Regulatory Review Progress: Additionally, Dr. Reddy's generic version of Wegovy is currently undergoing regulatory review in India, further strengthening the company's position in the weight-loss drug market and potentially supporting future revenue growth.
See More
Asian Equities Surge as American Depositary Receipts Rise Sharply
- Market Recovery: On Wednesday, Asian equities showed strong performance during US trading hours, particularly with American Depositary Receipts (ADRs) rising sharply, indicating a rebound in investor confidence that could drive related companies' stock prices higher.
- Improved Investor Sentiment: The surge in ADRs reflects a notable improvement in market sentiment, suggesting that investors are optimistic about global economic recovery, which may lead to increased capital inflows into Asian markets.
- Increased Trading Volume: The strong performance of ADRs was accompanied by a significant increase in trading volume, indicating a rising interest among market participants in Asian companies, potentially resulting in higher liquidity and better market pricing.
- Positive Future Outlook: Analysts suggest that the upward trend in Asian equities may continue, especially against the backdrop of global economic recovery, prompting investors to focus more on investment opportunities in the Asian market.
See More
Dr. Reddy's (RDY) to Announce Q3 Earnings on January 21, 75% EPS Beat Rate
- Earnings Announcement: Dr. Reddy's is set to release its Q3 earnings report on January 21 before the market opens, generating anticipation among investors regarding its performance.
- EPS Beat Rate: Over the past year, Dr. Reddy's has exceeded earnings per share (EPS) estimates 75% of the time, indicating a consistent ability to deliver strong financial results.
- Revenue Performance: The company has impressively beaten revenue estimates 100% of the time in the last year, showcasing robust market demand and effective execution strategies.
- Market Sentiment: Despite facing exaggerated headwinds, Dr. Reddy's is viewed as having an underappreciated future potential, drawing attention from investors looking for growth opportunities.
See More
Dr. Reddy's Launches 0.7% Olopatadine OTC Eye Drops with $69.9M Market Potential
- Market Launch: Dr. Reddy's has launched a 0.7% antihistamine eye drop in the U.S., becoming the first to market with this product, which is expected to significantly enhance its market share in the OTC eye care sector.
- Sales Potential: According to NIQ data, the Pataday® brand generated approximately $69.9 million in U.S. sales over the past 52 weeks, positioning Dr. Reddy's new product for rapid growth leveraging this market foundation.
- Product Portfolio Expansion: The introduction of this new product enriches Dr. Reddy's existing OTC eye care lineup, further strengthening its competitive edge in the consumer brand market.
- Retail Collaboration Enhancement: The CEO of Dr. Reddy's stated that this launch will deepen collaboration with retail customers, driving the company's strategic positioning in the OTC market and enhancing brand influence.
See More
